IQ-AI Limited (LON:IQAI) FDA Clearance to Market for StoneChecker Software

IQ-AI Announce FDA ‘Clearance to Market’ For StoneChecker Software

Imaging Biometrics, IQ-AI’s Milwaukee based subsidiary, today received notification that the FDA has cleared StoneChecker Software for marketing in the USA.

David Smith, Chief Executive of the operating subsidiaries of IQ-AI stated, “We are delighted that after an exhaustive review of the product, that the FDA has cleared the product for marketing in the USA.”

A further announcement will be issued in the next few days, outlining the scale of the market opportunity for the product in the USA and IQ-AI’s plans for introduction.

The Directors of the Company accept responsibility for the contents of this announcement.

 

-ENDS-

 

Register for the Share Talk investor evening, London 26th November 2019


Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates.

Terms of Website Use

All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Malcare WordPress Security